Organogenesis Holdings Inc. is a regenerative medicine company developing solutions for advanced wound care, surgical, and sports medicine markets. It offers bioactive and acellular biomaterials, including Apligraf for venous leg ulcers and diabetic foot ulcers (DFUs), Dermagraft for DFUs, PuraPly AM as an antimicrobial barrier, and placental allografts like Affinity, Novachor, and NuShield. In sports medicine, products include NuShield as a surgical barrier and PuraForce for soft tissue repairs, along with PuraPly MZ, PuraPly AM, and PuraPly SX for managing open wounds in surgical settings. The ORGO YTD return is shown above.
The YTD Return on the ORGO YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether ORGO YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ORGO YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|